Re; Biowatch--Continuation of GTCB/MEDX post. Thanks for the info. I agree that anti-EGFR, anti-RANKL, and manufacturing capacity were the driving forces in the ABGX acquisition. AMGN emphasized anti-EGFR in its press releases. However, IMO the anti-RANKL royalties were a critical part of the deal. ABGX also had an anti-PTH antibody program. I do not see any mention of this program in AMGN’s current pipeline. Anti-PTH addresses secondary hyperparathyroidism commonly seen in chronic renal disease so it would seem to be a key strategic fit with AMGN. AMGN also has Sensipar for secondary hyperparathyroidism (not sure if AMGN wants/needs two products treating this indication). So I was wondering if the anti-PTH program was still active at AMGN. If anyone knows please let me know. Below, I’ve cut and pasted info on ABX-PTH from a press release.
Regards,
biophud
ABX-PTH
The following three abstracts for ABX10241 (also known as ABX-PTH), the company's fully human monoclonal antibody that targets and neutralizes the action of parathyroid hormone (PTH), will be presented at the 26th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Seattle, Wash., Oct. 1 - 5, 2004:
"Generation and Therapeutic Potential of ABX10241, A Fully Human Neutralizing Monoclonal Antibody to Human Parathyroid Hormone," (Oral Presentation #1201, Tue., Oct. 5)
"Treatment of Parathyroid Carcinoma with ABX10241, a Monoclonal Antibody to Parathyroid
Hormone," (Poster Presentation #SA498, Sat., Oct. 2)
"A Phase 1, Single-Dose Study of ABX10241, A Fully Human Monoclonal Antibody to Parathyroid Hormone Secondary Hyperparathyroidism (SHPT) Patients," (Poster Presentation #SU530, Sun., Oct. 3)
The following two abstracts for ABX-PTH will be presented at the American Society of Nephrology (ASN) 37th Annual Meeting & Scientific Exposition in St. Louis, Mo., Oct. 29 - Nov. 1, 2004:
"Results of a Double-Blind, Single Dose, Dose Escalation Study of a Fully Human Monoclonal Antibody to PTH (ABX10241) in Patients with Secondary Hyperparathyroidism (SHPT)," (Oral Presentation, Room 260, Sat., Oct. 30)
"Treatment of Severe Hyperparathyroidism Secondary to Parathyroid Cancer with ABX10241, a Fully Human Monoclonal Antibody Directed Against Parathyroid Hormone," (Poster Presentation #F-PO981, Fri., Oct. 29)
AI
